Agilent (A)
NYSE:A
Want to see A full AI Analyst Report?
Top Page
Agilent
(NYSE:A)
Select Model
Select Model
Rating:66Neutral
Price Target:
$120.00
▼(-1.53% Downside)
Action:ReiteratedDate:03/21/26
The score is driven most by solid underlying fundamentals and a constructive earnings-call outlook (maintained growth guidance, raised EPS, and margin-expansion/tariff-mitigation plans). These positives are meaningfully offset by a weak technical setup (below key moving averages with negative momentum) and a relatively high P/E with a low dividend yield.
Positive Factors
Recurring Consumables & Services
Agilent's business mix includes high-margin recurring consumables, software and services tied to an installed instrument base. That model yields predictable annuity-like revenue, supports margin resilience vs. one-time instrument sales, and underpins steady cash generation as installed units grow.
Negative Factors
Tariff-Driven Margin Pressure
Tariff-related cost increases have materially compressed gross margin versus historical levels. Mitigation via pricing, localization and Ignite savings will take quarters to fully offset, leaving structural margin volatility and execution risk if tariffs or supply costs persist.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring Consumables & Services
Agilent's business mix includes high-margin recurring consumables, software and services tied to an installed instrument base. That model yields predictable annuity-like revenue, supports margin resilience vs. one-time instrument sales, and underpins steady cash generation as installed units grow.
Read all positive factors
Agilent (A) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$32.67B
Dividend Yield0.72%
Average Volume (3M)1.97M
Price to Earnings (P/E)31.0
Beta (1Y)0.98
Revenue Growth8.14%
EPS Growth4.17%
CountryUS
Employees17,900
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)1.36
Shares Outstanding282,602,330
10 Day Avg. Volume1,863,412
30 Day Avg. Volume1,968,838
Financial Highlights & Ratios
PEG Ratio9.41
Price to Book (P/B)6.14
Price to Sales (P/S)5.96
P/FCF Ratio35.95
Enterprise Value/Market Cap1.04
Enterprise Value/Revenue4.82
Enterprise Value/Gross Profit9.23
Enterprise Value/Ebitda18.67
Forecast
1Y Price Target
$158.62Price Target Upside30.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)5.97
Revenue Forecast (FY)$7.40B
Agilent Business Overview & Revenue Model
Company Description
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid ...
How the Company Makes Money
Agilent makes money primarily by selling laboratory products and related services to research, quality-control, and clinical testing labs. Its revenue model is a mix of (1) capital equipment sales, where customers purchase higher-priced analytical...
Agilent Key Performance Indicators (KPIs)
Any
Revenue by Geography
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Data provided by:
The Fly
The FlyAgilent Earnings Call Summary
Earnings Call Date:Feb 25, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:May 26, 2026
Earnings Call Sentiment Positive
The call presented a broadly positive operational and financial picture: solid top-line growth, maintained full‑year guidance, strong product and commercial momentum (notably in pharma/GLP‑1, CAM/advanced materials, Infinity III and Pro iQ), healthy cash generation and clear benefits from the Ignite operating program. Near-term headwinds—tariff-driven gross margin pressure, an isolated weather disruption (~$10M), and pockets of softness in academia/government, cell analysis and certain smaller end markets—were acknowledged but framed as manageable through pricing, supply‑chain actions and Ignite-led savings. Management maintained disciplined capital allocation, reiterated mid‑term growth drivers (replacement cycles, CDMO expansion, reshoring of semiconductor/pharma manufacturing) and emphasized integration/M&A readiness. Overall, positive execution and momentum outweigh the identified challenges.Positive Updates
Revenue and Core Growth
Q1 revenue of $1.8 billion; core (adjusted) revenue growth of 4.4% year-over-year and reported growth of 7.0%; currency contributed a 2.6% tailwind to reported growth.
Negative Updates
Tariff and Gross Margin Pressure
Q1 gross margin declined to 53.7%, down ~100 basis points year-over-year primarily due to tariff headwinds; operating margin down ~50 basis points year-over-year with tariff expense and normalized performance-based pay cited as contributors.
Read all updates
Q1-2026 Updates
Positive
Negative
Revenue and Core Growth
Q1 revenue of $1.8 billion; core (adjusted) revenue growth of 4.4% year-over-year and reported growth of 7.0%; currency contributed a 2.6% tailwind to reported growth.
Read all positive updates
Company Guidance
Agilent maintained full-year FY‑26 core revenue guidance of 4%–6% (reported revenue $7.3–$7.5B) and raised its EPS range to $5.90–$6.04 (a 5.5%–8% increase, with a $0.04 benefit from FX), assuming a ~1.5% currency tailwind for the year; Q2 guidance calls for core growth of roughly 4%–5.5% (reported revenue $1.79–$1.82B) and EPS of $1.39–$1.42 (≈7% growth at the midpoint), with Q2 FX ~+3% and the majority of the $10M Q1 storm impact expected to be recovered; the company is targeting ~75 bps of operating margin expansion for the year (Q1 operating margin was 24.6% and Q2 is expected to improve ~100 bps sequentially), assumes a 14.5% tax rate, $22M of other income, 283M diluted shares, at least +100 bps pricing contribution (via Ignite), tariffs largely mitigated by H2 through cost savings/pricing, operating cash flow of $1.6–$1.7B, and ~ $500M of full‑year capex.Agilent Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
74
Positive
Cash Flow
66
Positive
| Breakdown | TTM | Oct 2025 | Oct 2024 | Oct 2023 | Oct 2022 | Oct 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.07B | 6.95B | 6.51B | 6.83B | 6.85B | 6.32B |
| Gross Profit | 3.69B | 3.64B | 3.54B | 3.46B | 3.72B | 3.41B |
| EBITDA | 1.82B | 1.83B | 1.87B | 1.70B | 1.91B | 1.76B |
| Net Income | 1.29B | 1.30B | 1.29B | 1.24B | 1.25B | 1.21B |
Balance Sheet | ||||||
| Total Assets | 12.81B | 12.73B | 11.85B | 10.76B | 10.53B | 10.71B |
| Cash, Cash Equivalents and Short-Term Investments | 1.76B | 1.79B | 1.33B | 1.59B | 1.05B | 1.57B |
| Total Debt | 3.35B | 3.35B | 3.57B | 2.73B | 2.77B | 2.73B |
| Total Liabilities | 5.91B | 5.99B | 5.95B | 4.92B | 5.23B | 5.32B |
| Stockholders Equity | 6.91B | 6.74B | 5.90B | 5.84B | 5.30B | 5.39B |
Cash Flow | ||||||
| Free Cash Flow | 993.00M | 1.15B | 1.37B | 1.47B | 1.02B | 1.30B |
| Operating Cash Flow | 1.40B | 1.56B | 1.75B | 1.77B | 1.31B | 1.49B |
| Investing Cash Flow | -393.00M | -394.00M | -1.26B | -310.00M | -338.00M | -749.00M |
| Financing Cash Flow | -757.00M | -715.00M | -752.00M | -930.00M | -1.37B | -696.00M |
Agilent Technical Analysis
Neutral
121.87
Price Trends
118.29
Positive
129.85
Negative
129.25
Negative
Market Momentum
0.61
Negative
61.53
Neutral
78.83
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For A, the sentiment is Neutral. The current price of 121.87 is above the 20-day moving average (MA) of 115.12, above the 50-day MA of 118.29, and below the 200-day MA of 129.25, indicating a neutral trend. The MACD of 0.61 indicates Negative momentum. The RSI at 61.53 is Neutral, neither overbought nor oversold. The STOCH value of 78.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for A.
Agilent Risk Analysis
Agilent disclosed 35 risk factors in its most recent earnings report. Agilent reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Agilent Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $173.93B | 26.66 | 13.26% | 0.30% | 5.36% | 6.54% | |
66 Neutral | $32.67B | 31.05 | 19.73% | 0.72% | 8.14% | 4.17% | |
66 Neutral | $127.84B | 31.22 | 7.06% | 0.53% | 4.02% | 0.05% | |
66 Neutral | $25.91B | 33.06 | -487.21% | ― | 3.98% | 3.77% | |
66 Neutral | $29.43B | 35.17 | 28.52% | ― | 6.99% | 0.47% | |
63 Neutral | $27.80B | 28.49 | 22.28% | ― | 5.84% | 4.62% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
A
Agilent
114.87
8.29
7.77%
DHR
Danaher
178.98
-18.59
-9.41%
MTD
Mettler-Toledo
1,262.48
197.25
18.52%
TMO
Thermo Fisher
470.22
44.26
10.39%
WAT
Waters
300.73
-40.09
-11.76%
IQV
IQVIA Holdings
158.98
5.53
3.60%
Agilent Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Agilent Shareholders Approve Board Declassification and Governance Changes
Positive
Mar 20, 2026
At its March 18, 2026 annual meeting, Agilent stockholders approved a Fourth Amended and Restated Certificate of Incorporation to declassify the board of directors over three years, and the board adopted corresponding Fourth Amended and Restated B...
Executive/Board Changes
Agilent Announces Planned Retirement of Principal Accounting Officer
Neutral
Mar 6, 2026
On March 5, 2026, Agilent Technologies said Vice President, Corporate Controller and Principal Accounting Officer Rodney Gonsalves plans to retire from his roles in January 2027, with the exact date to be set later. The company emphasized that his...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.